A long-anticipated pruning back of the ev vivo gene therapy pipeline for sickle cell disease has arrived with Novartis, Graphite Bio and Sangamo each dropping projects, but some challengers are looking ahead to a future of in vivo approaches to the condition.

The European Medicines Agency has started reviewing a new batch of medicines for potential pan-EU marketing approval.

Chief operating officer Stuart Arbuckle and chief scientific officer David Altshuler talked to Scrip about potential launches in sickle cell disease and pain, and the firm’s expanding pipeline.

Panelists at the BIO CEO and Investor Conference foresee some changes coming as biotech investors become more judicious about where they park their money.